Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed Feb 17, 2026 · 10-Q · 48 days after period end · 0001104659-26-016554
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$23.06M | $17.38M | -$11.18M | -$18.66M |
| EPS Diluted | -$0.38 | $0.72 | -$0.86 | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Feb 17, 2026 · 48 d after period end
